2023
Bridging Radiotherapy Prior to Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphomas: An ILROG Multi-Institutional Study
Yegya-Raman N, Wright C, Ladbury C, Chew J, Zhang S, Sun S, Burke S, Baron J, Sim A, LaRiviere M, Yang J, Robinson T, Tseng Y, Terezakis S, Braunstein S, Dandapani S, Schuster S, Chong E, Plastaras J, Figura N. Bridging Radiotherapy Prior to Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphomas: An ILROG Multi-Institutional Study. International Journal Of Radiation Oncology • Biology • Physics 2023, 117: s50-s51. DOI: 10.1016/j.ijrobp.2023.06.333.Peer-Reviewed Original ResearchImmune effector cell-associated neurotoxicity syndromeProgression-free survivalCytokine release syndromeB-cell lymphomaChimeric antigen receptor T-cell therapySuperior progression-free survivalLarge B-cell lymphomaCAR-T infusionT-cell therapyMulti-institutional studyOverall survivalCTCAE v5.0T infusionTisa-celCAR TRefractory aggressive B-cell lymphomasStage III/IV diseaseT-cell/histiocyte-rich large B-cell lymphomaFavorable progression-free survivalCentral nervous system involvementDiffuse large B-cell lymphomaAggressive B-cell lymphomasPrimary mediastinal B-cell lymphomaMediastinal B-cell lymphomaNervous system involvement
2021
Immune Cell Infiltrates of the Tumor Microenvironment and Radiosensitivity of Recurrent Glioblastomas and Their Association With Outcome
Rishi A, Mohammadi H, Martir D, Welsh E, Robinson T, Oliver D, Eschrich S, Torres-Roca J, Yu H, Grass D, Ahmed K. Immune Cell Infiltrates of the Tumor Microenvironment and Radiosensitivity of Recurrent Glioblastomas and Their Association With Outcome. International Journal Of Radiation Oncology • Biology • Physics 2021, 111: s123. DOI: 10.1016/j.ijrobp.2021.07.281.Peer-Reviewed Original ResearchImmune cell infiltratesProgression-free survivalAffected overall survivalOverall survivalHelper T cellsRadiosensitivity indexCell infiltrateClinical trialsT cellsPrimary GBMMedian progression-free survivalLack of monocytesNLR/PLRHigh expressionPoor prognostic factorCurrent smoking statusKaplan-Meier estimatesLog-rank testLow-grade gliomasMATERIAL/METHODSAssociation of factorsICI subtypesRGBM patientsAdjuvant radiotherapyFree survivalNivolumab and stereotactic radiosurgery for patients with breast cancer brain metastases: A non-randomized, open-label phase Ib study.
Ahmed K, Kim Y, Arrington J, Kim S, DeJesus M, Soyano A, Armaghani A, Costa R, Khong H, Rosa M, Caudell J, Diaz R, Robinson T, Etame A, Tran N, Sahebjam S, Soliman H, Forsyth P, Yu H, Han H. Nivolumab and stereotactic radiosurgery for patients with breast cancer brain metastases: A non-randomized, open-label phase Ib study. Journal Of Clinical Oncology 2021, 39: e14010-e14010. DOI: 10.1200/jco.2021.39.15_suppl.e14010.Peer-Reviewed Original ResearchBreast cancer brain metastasesCancer brain metastasesProgression-free survivalBrain metastasesStereotactic radiosurgeryBrain metastasis controlStudy therapyControl rateMetastasis controlCertain breast cancer patientsNeuro-Oncology Brain MetastasesSystemic progression-free survivalDose of nivolumabNeurologic adverse eventsImmune checkpoint inhibitionPhase Ib studyPhase Ib trialSolid Tumors criteriaResponse Evaluation CriteriaKey eligibility criteriaTumor control rateFeasible treatment optionBreast cancer patientsBrain metastasis managementExtracranial disease